# The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers

> **NCT05200728** · PHASE1 · COMPLETED · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 68 (actual)

## Conditions studied

- Acute Ischemic Stroke
- Cerebral Edema

## Interventions

- **DRUG:** SIM1910-09
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05200728
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-06
- **Primary completion:** 2023-03-23
- **Final completion:** 2023-03-23
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2023-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05200728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05200728, "The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05200728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*